AAAAAA

   
Results: 1-7 |
Results: 7
Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatmentduring ovarian stimulation for conventional IVF or ICSI: a preliminary report
Authors: Olivennes, F Mannaerts, B Struijs, M Bonduelle, M Devroey, P
Citation: F. Olivennes et al., Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatmentduring ovarian stimulation for conventional IVF or ICSI: a preliminary report, HUM REPR, 16(8), 2001, pp. 1588-1591
GnRH antagonists do not activate the GnRH receptor
Authors: Mannaerts, B Gordon, K
Citation: B. Mannaerts et K. Gordon, GnRH antagonists do not activate the GnRH receptor, HUM REPR, 15(9), 2000, pp. 1882-1883
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report
Authors: Itskovitz-Eldor, J Kol, S Mannaerts, B
Citation: J. Itskovitz-eldor et al., Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report, HUM REPR, 15(9), 2000, pp. 1965-1968
Treatment with gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial (vol 15, pg 1490, 2000)
Authors: Borm, G Mannaerts, B
Citation: G. Borm et B. Mannaerts, Treatment with gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial (vol 15, pg 1490, 2000), HUM REPR, 15(8), 2000, pp. 1877-1877
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix inwomen undergoing ovarian stimulation with recombinant follicle stimulatinghormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial
Authors: Borm, G Mannaerts, B
Citation: G. Borm et B. Mannaerts, Treatment with the gonadotrophin-releasing hormone antagonist ganirelix inwomen undergoing ovarian stimulation with recombinant follicle stimulatinghormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial, HUM REPR, 15(7), 2000, pp. 1490-1498
Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran (R)) administration by Medi-Jector (R) compared to conventional needle injections
Authors: Oberye, J Mannaerts, B Huisman, J Timmer, C
Citation: J. Oberye et al., Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran (R)) administration by Medi-Jector (R) compared to conventional needle injections, HUM REPR, 15(2), 2000, pp. 245-249
High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
Authors: Kol, S Lightman, A Hillensjo, T Devroey, P Fauser, B Tarlatzis, B Mannaerts, B Itskovitz-Eldor, J
Citation: S. Kol et al., High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles, HUM REPR, 14(9), 1999, pp. 2242-2244
Risultati: 1-7 |